Four studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition spotlight how re-examining existing practices can illuminate new approaches, or the need for new ...
Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has d ...
A cluster of viral mutations seems to be speeding the spread of COVID-19—and scientists are racing to understand how they ...
Evolution is neither purposeful nor intentional: it has no ideal, aim, or end-point. For evolutionary change, there are no ...
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback